Skip to main content

Advertisement

SpringerLink
Log in

Meta-Analysis: The Impact of Nutritional Status on the Immune Response to Hepatitis B Virus Vaccine in Chronic Kidney Disease

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Patients with chronic kidney disease (CKD) typically show a diminished immune response to hepatitis B virus (HBV) vaccine compared with individuals with intact kidney function. A number of inherited or acquired factors have been implicated in this suboptimal response. Patients with chronic kidney disease frequently have a compromised nutritional status; however, the impact of malnutrition on the immune response to hepatitis B virus vaccine in chronic kidney disease patients remains unclear.

Aim

To evaluate the influence of nutrition status on the immune response to HBV vaccine in CKD population by performing a systematic review of the literature with a meta-analysis of clinical studies.

Methods

Study-specific relative risks were weighted by the inverse of their variance to obtain fixed- and random-effects pooled estimates of impaired vaccine response across the published studies. The risk of poor serological response to HBV vaccine in chronic kidney disease population according to nutritional parameters was regarded as the most reliable outcome end-point. Only studies performing multivariate analysis in order to make adjustments for potential confounders were included.

Results

We identified seven studies (15,172 unique patients with CKD). The serum protection rate after a full course of recombinant or plasma-derived vaccine towards HBV ranged between 40 and 86%. Aggregation of study results showed an independent and adverse effect of poor nutrition status, as mostly detected by serum albumin levels, on the protection rate after HBV vaccine course; the summary estimate for adjusted RR was 1.50 with a 95% confidence interval (CI) of 1.02, 2.21; R i  = 0.01 (random-effects model). The P value for study heterogeneity was significant (Q = 0.0001). In the subgroup of patients who received HBV recombinant vaccine, the relative risk of impaired serological response after HBV vaccination was 1.63 (95% CI, 1.08, 2.45), R i  = 0.90, Q = 0.00001, with poor nutritional parameters at baseline.

Conclusions

An increased risk exists of impaired serologic response to HBV vaccine response among chronic kidney disease patients having poor nutrition status. Additional studies are needed to understand better the mechanisms underlying the relationship between nutritional status and serological response to HBV vaccine among patients with CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Labriola L, Jadoul M. The decades-long fight against HBV transmission to dialysis patients: slow but definite progress. Nephrol Dial Transplant. 2010;25:2047–2049.

    Article  PubMed  Google Scholar 

  2. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States. Semin Dial. 2005;18:52–61.

    Article  PubMed  Google Scholar 

  3. Thompson ND, Perez JF, Moorman AC, Holmberg SD. Nonhospital health-care associated hepatitis B and C virus transmission: United States, 1998–2008. Ann Intern Med. 2009;150:33–39.

    PubMed  Google Scholar 

  4. Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in haemodialysis units from three continents: the DOPPS. Kidney Int. 2003;63:2222–2229.

    Article  PubMed  Google Scholar 

  5. Rangel M, Coronado V, Euler G, Strikas R. For the Advisor Committee on Immunization Practices and the American Academy of Pediatrics. Vaccine recommendations for patients on chronic dialysis. Semin Dial. 2002;13:101–107.

    Article  Google Scholar 

  6. Chandra RK. Cellular and molecular basis of nutrition-immunity interactions. Adv Exp Med Biol. 1990;262:13–18.

    Article  PubMed  CAS  Google Scholar 

  7. Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests for heterogeneity in epidemiologic meta-analysis. Am J Epidemiol. 1999;150:206–215.

    Article  PubMed  CAS  Google Scholar 

  8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.

    Article  PubMed  CAS  Google Scholar 

  9. Costa-Bouzas J, Takkouche B, Cadarso-Suarez C, Spiegelman D. HepiMA: software for the identification of heterogeneity in meta-analysis. Comput Methods Progr Biomed. 2001;64:101–107.

    Article  CAS  Google Scholar 

  10. DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42:1184–1192.

    Article  PubMed  Google Scholar 

  11. Chin A. Hepatitis B virus vaccine response in haemodialysis: baseline patient characteristics. Hemodial Int. 2003;7:296–303.

    Article  PubMed  Google Scholar 

  12. Weinstein T, Chagnac A, Boaz M, et al. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract. 2004;97:c67–c72.

    Article  PubMed  CAS  Google Scholar 

  13. Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, Lazarus J. Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease. Hemodial Int. 2005;9:367–375.

    Article  PubMed  Google Scholar 

  14. Chow K, Law M, Leung C, Szeto C, Li P. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract. 2006;103:c89–c93.

    Article  PubMed  Google Scholar 

  15. Liu J, Liu Y, Lin H, et al. Intravenous iron attenuates post-vaccination anti-HBsAg titers after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy. Int J Clin Pract. 2009;63:387–393.

    Article  PubMed  CAS  Google Scholar 

  16. Afsar B, Elsurer R, Eyileten T, Yilmaz M, Caglar K. Antibody response following hepatitis B vaccination in dialysis patients: does depression and life quality matter? Vaccine. 2009;27:5865–5869.

    Article  PubMed  CAS  Google Scholar 

  17. Fernandez E, Betriu M, Gomez R, Montoliu J. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant. 1996;11:1559–1563.

    Article  PubMed  CAS  Google Scholar 

  18. Morais E, Resende M, Oliveira A, et al. Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: immunogenicity and follow-up. Aliment Pharmacol Ther. 2007;25:849–855.

    Article  PubMed  CAS  Google Scholar 

  19. Fabrizi F, Di Filippo S, Marcelli D, et al. Recombinant hepatitis B vaccine use in chronic haemodialysis patients. Nephron. 1996;72:536–543.

    Article  PubMed  CAS  Google Scholar 

  20. Kara I, Yilmaz M, Suner A, Kadiroglu A, Isikoglu B. The evaluation of immune responses that occur after HBV infection and HBV vaccination in haemodialysis patients. Vaccine. 2004;22:3963–3967.

    Article  PubMed  Google Scholar 

  21. Lombardi M, Pizzarelli F, Righi M, et al. Hepatitis B vaccination in dialysis patients and nutritional status. Nephron. 1992;61:266–268.

    Article  PubMed  CAS  Google Scholar 

  22. Vagelli G, Calabrese G, Mazzotta A, Pratesi G, Gonella M. More about response to hepatitis B vaccine in haemodialysis patients. Nephron. 1988;49:171.

    Article  PubMed  CAS  Google Scholar 

  23. Chow K, Lo S, Szeto C, et al. Extra-high-dose hepatitis B vaccination does not confer longer seroprotection in peritoneal dialysis patients: a randomized controlled trial. Nephrol Dial Transplant. 2010;25:2303–2309.

    Article  PubMed  CAS  Google Scholar 

  24. Radziszewski A, Gajda M, Pituch-Noworolska A, et al. The evaluation of the effectiveness of multiple dose intradermal hepatitis B re-vaccination in haemodialysis patients not responding to standard method of immunization. Prezegl Lek. 2007;64:470–475.

    Google Scholar 

  25. Verkade M, Druningen C, op de Hoek C, Weimar W, Betjes M. Decreased antigen-specific T-cell proliferation by moDC among hepatitis B vaccine non-responders on haemodialysis. Clin Exp Med. 2007;7:65–71.

    Article  PubMed  CAS  Google Scholar 

  26. Mak R, Ikizler A, Kovesdy C, Raj D, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2011;2:9–25.

    Article  PubMed  Google Scholar 

  27. Liu Y, Kao M, Huang C. A comparison of responsiveness to hepatitis B vaccination in patients on haemodialysis and peritoneal dialysis. Vaccine. 2005;23:3957–3960.

    Article  PubMed  CAS  Google Scholar 

  28. Peces R, de la Torre M, Alcazar R, Urra J. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in haemodialysis patients. Am J Kidney Dis. 1997;29:239–245.

    Article  PubMed  CAS  Google Scholar 

  29. Elwell R, Neumann M, Bailie G. Factors associated with long-term antibody production induced by hepatitis B vaccine in patients undergoing haemodialysis: a retrospective cohort study. Pharmacotherapy. 2003;23:1558–1563.

    Article  PubMed  Google Scholar 

  30. Navarro J, Teruel J, Mateos M, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in haemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol. 1996;16:95–97.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors’ work is supported in part by the grant ‘Project Glomerulonephritis’; in memory of Pippo Neglia.

Conflict of interest

The authors of this manuscript have no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Division of Nephrology and Dialysis, Maggiore Hospital, IRCCS Foundation, Pad. Croff, Via Commenda 15, 20122, Milan, Italy

    Fabrizio Fabrizi & Piergiorgio Messa

  2. Division of Hepatology, School of Medicine, University of Miami, Miami, FL, USA

    Vivek Dixit & Paul Martin

  3. Division of Nephrology, Cliniques Universitaires St. Luc, Universitè Catholique de Louvain, Brussels, Belgium

    Michel Jadoul

Authors
  1. Fabrizio Fabrizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vivek Dixit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michel Jadoul
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Piergiorgio Messa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabrizio Fabrizi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fabrizi, F., Dixit, V., Martin, P. et al. Meta-Analysis: The Impact of Nutritional Status on the Immune Response to Hepatitis B Virus Vaccine in Chronic Kidney Disease. Dig Dis Sci 57, 1366–1372 (2012). https://doi.org/10.1007/s10620-011-1987-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-011-1987-1

Keywords

Search

Navigation